Vertex Pharmaceuticals Inc Cash Flow Conversion Efficiency
Vertex Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) has a cash flow conversion efficiency ratio of 0.056x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.13 Billion) by net assets ($20.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VRTX market cap overview for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Vertex Pharmaceuticals Inc (1991–2025)
Cash flow conversion efficiency of Vertex Pharmaceuticals Inc from 1991 to 2025. This chart illustrates how Vertex Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Vertex Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Vertex Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Vertex Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vertex Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vertex Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Review VRTX free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iberdrola S.A.
MC:IBE
|
0.049x |
|
Anheuser Busch Inbev SA NV
BR:ABI
|
0.124x |
|
Eaton Corporation PLC
F:3EC
|
0.026x |
|
China Merchants Bank Co Ltd
SHG:600036
|
0.030x |
|
Foxconn Industrial Internet Co Ltd
SHG:601138
|
0.053x |
|
Deutsche Telekom AG
F:DTEA
|
0.115x |
|
Bristol-Myers Squibb Company
NYSE:BMY
|
0.152x |
|
ABB Ltd
SW:ABBN
|
0.117x |
Annual Cash Flow Conversion Efficiency for Vertex Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Vertex Pharmaceuticals Inc from 1991 to 2025. Also see how large is Vertex Pharmaceuticals Inc's balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.67 Billion | $3.63 Billion | 0.195x | +748.08% |
| 2024-12-31 | $16.41 Billion | $-492.60 Million | -0.030x | -114.92% |
| 2023-12-31 | $17.58 Billion | $3.54 Billion | 0.201x | -32.22% |
| 2022-12-31 | $13.91 Billion | $4.13 Billion | 0.297x | +13.41% |
| 2021-12-31 | $10.10 Billion | $2.64 Billion | 0.262x | -30.12% |
| 2020-12-31 | $8.69 Billion | $3.25 Billion | 0.375x | +45.23% |
| 2019-12-31 | $6.09 Billion | $1.57 Billion | 0.258x | -9.96% |
| 2018-12-31 | $4.44 Billion | $1.27 Billion | 0.286x | -30.77% |
| 2017-12-31 | $2.04 Billion | $844.94 Million | 0.414x | +134.49% |
| 2016-12-31 | $1.34 Billion | $236.10 Million | 0.176x | +152.76% |
| 2015-12-31 | $1.09 Billion | $-365.43 Million | -0.334x | +28.46% |
| 2014-12-31 | $1.10 Billion | $-513.20 Million | -0.467x | -1129.56% |
| 2013-12-31 | $1.36 Billion | $-51.57 Million | -0.038x | -117.52% |
| 2012-12-31 | $1.23 Billion | $267.84 Million | 0.217x | +45.75% |
| 2011-12-31 | $965.51 Million | $143.74 Million | 0.149x | +111.81% |
| 2010-12-31 | $503.97 Million | $-635.44 Million | -1.261x | -223.29% |
| 2009-12-31 | $1.10 Billion | $-427.59 Million | -0.390x | +58.87% |
| 2008-12-31 | $238.87 Million | $-226.48 Million | -0.948x | -1.88% |
| 2007-12-31 | $271.30 Million | $-252.48 Million | -0.931x | -1994.95% |
| 2006-12-31 | $505.94 Million | $-22.48 Million | -0.044x | +93.82% |
| 2005-12-31 | $239.18 Million | $-172.05 Million | -0.719x | +82.07% |
| 2004-12-31 | $35.44 Million | $-142.16 Million | -4.011x | -361.47% |
| 2003-12-31 | $192.84 Million | $-167.62 Million | -0.869x | -313.72% |
| 2002-12-31 | $378.58 Million | $-79.54 Million | -0.210x | -1136.94% |
| 2001-12-31 | $475.35 Million | $-8.07 Million | -0.017x | +64.72% |
| 2000-12-31 | $345.76 Million | $-16.64 Million | -0.048x | +68.33% |
| 1999-12-31 | $209.19 Million | $-31.80 Million | -0.152x | -20.34% |
| 1998-12-31 | $246.20 Million | $-31.10 Million | -0.126x | -270.90% |
| 1997-12-31 | $276.00 Million | $-9.40 Million | -0.034x | +88.95% |
| 1996-12-31 | $130.80 Million | $-40.30 Million | -0.308x | -64.26% |
| 1995-12-31 | $85.30 Million | $-16.00 Million | -0.188x | -34.62% |
| 1994-12-31 | $105.50 Million | $-14.70 Million | -0.139x | -180.20% |
| 1993-12-31 | $49.50 Million | $8.60 Million | 0.174x | +243.91% |
| 1992-12-31 | $43.90 Million | $-5.30 Million | -0.121x | -152.08% |
| 1991-12-31 | $52.20 Million | $-2.50 Million | -0.048x | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more